Aromatase Inhibitors

Evaluation of Clinical Impact of Interruption VS Maintenance of AI in Patients With Locally Advanced/ Metastatic Low Grade Endometrial Stromal Sarcoma (LGESS)

Endocrine Therapy Fulvestrant & Palbociclib or Aromatase Inhibitor Therapy in Treating Older Patients With Hormone Responsive Breast Cancer That Cannot Be Removed by Surgery

PAlbociclib and Circulating Tumor DNA for ESR1 Mutation Detection

Study Evaluating Abemaciclib + Aromatase Inhibitors in HR+, HER2- Advanced Breast Cancer Patients (HERMIONE-7)

Impact of Endocrine Therapy and Abemaciclib on Host and Tumor Immune Cell Repertoire/Function in Advanced ER+/HER2- Breast Cancer

Niraparib Plus Aromatase Inhibitors for Luminal-like(HER2-,ER+) and gBRCA or HDR+ Metastatic Breast Cancer (LUZERN)

Adjuvant Ovarian Suppression Plus Aromatase Inhibitor or Tamoxifen in Young Women

Maintenance Aromatase Inhibitors (AIs)+ Everolimus vs AIs in Hormone Receptor Positive Metastatic Breast Cancer Patients

Trial of Perioperative Endocrine Therapy - Individualising Care

Pyrotinib Combined With Trastuzumab Plus Aromatase Inhibitor in Treatment of Breast Cancer

SFX-01 in the Treatment and Evaluation of Metastatic Breast Cancer

Dovitinib Plus an Aromatase Inhibitor for Metastatic Breast Cancer

HOrmone Therapy Immediately After Histological Diagnosis of Breast Cancer

Effects of Testosterone and Fat Utilization

Impact of Chemotherapy Followed by Aromatase Inhibitors on Bone Health of Women With ER-positive Early Breast Cancer

Overcoming Endocrine Resistance in Metastatic Breast Cancer

Research Of Quality Of Life And Safety Outcomes Of Postmenopausal Breast Cancer Patients Switching From Tamoxifen Therapy To Aromatase Inhibitor Therapy